Fig. 2

Receiver Operating Characteristic (ROC) curve analysis for the total data set, the single chemotherapy, the combination chemotherapy and the data sets from Kern and Weisenthal. a Tumor samples from 52 ovarian cancer patients (total data set Charité Berlin, 2012) were used. A CTR-Test was performed and patients were treated with a monotherapy, a monotherapy plus Avastin or a combination chemotherapy which was tested by the CTR-Test. The individual patients were evaluated regarding their clinical response (responder or non-responder) and their CTR-Test result (SR, MR or ER) (see Table 3). A ROC curve analysis was performed for our total data set and for data from Kern and Weisenthal 1990 (total data set and ovarian cancer) to investigate whether the CTR-Test is able to predict the clinical response. AUC total data set Charité Berlin 2012: 0.7604; 95% CI: 0.6328–0.888. AUC total data set Kern and Weisenthal 1990: 0.7904; 95% CI: 0.7565–0.8242. AUC ovarian cancer Kern and Weisenthal 1990: 0.8438; 95% CI: 0.7622–0.9253. b Tumor samples from 19 ovarian cancer patients (Charité Berlin, 2012) were used. A CTR-Test was performed and the patients were treated with a monotherapy or a monotherapy plus Avastin. The monotherapy was tested by the CTR-Test. Patients were evaluated as described above. A ROC curve analysis was performed for our data and for data from Kern and Weisenthal 1990 (single agent chemotherapy). AUC single agent chemotherapy Kern and Weisenthal 1990: 0.811; 95% CI: 0.7728–0.8492. AUC single agent chemotherapy Charité Berlin 2012: 0.6923; 95% CI: 0.4741–0.9105. c Tumor samples from 33 ovarian cancer patients (Charité Berlin, 2012) were used. A CTR-Test was performed and the patients were treated with a combination chemotherapy which was tested by the CTR-Test. The patients were evaluated as described above. A ROC curve analysis was performed for our data and for data from Kern and Weisenthal 1990 (combination chemotherapy). AUC combination chemotherapy Kern and Weisenthal 1990: 0.6907; 95% CI: 0.6101–0.7713. AUC combination chemotherapy Charité Berlin 2012: 0.85; 95% CI: 0.6942–1